Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Mycosis Fungoides Therapeutics Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Small Molecules
  • 1.4.3 Biologics
• 1.5 Market by Application
  • 1.5.1 Global Mycosis Fungoides Therapeutics Market Share by Application (2019-2025)
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Mycosis Fungoides Therapeutics Market Size
• 2.2 Mycosis Fungoides Therapeutics Growth Trends by Regions
  • 2.2.1 Mycosis Fungoides Therapeutics Market Size by Regions (2019-2025)
  • 2.2.2 Mycosis Fungoides Therapeutics Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Mycosis Fungoides Therapeutics Market Size by by Players
  • 3.1.1 Global Mycosis Fungoides Therapeutics Revenue by by Players (2014-2019)
  • 3.1.2 Global Mycosis Fungoides Therapeutics Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Mycosis Fungoides Therapeutics Market Concentration Ratio (CR5 and HHI)
• 3.2 Mycosis Fungoides Therapeutics Key Players Head office and Area Served
• 3.3 Key Players Mycosis Fungoides Therapeutics Product/Solution/Service
• 3.4 Date of Enter into Mycosis Fungoides Therapeutics Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Mycosis Fungoides Therapeutics Market Size by Type (2014-2019)
• 4.2 Global Mycosis Fungoides Therapeutics Market Size by Application (2014-2019)

5 North America

• 5.1 North America Mycosis Fungoides Therapeutics Market Size (2014-2019)
• 5.2 Mycosis Fungoides Therapeutics Key Players in North America
• 5.3 North America Mycosis Fungoides Therapeutics Market Size by Type
• 5.4 North America Mycosis Fungoides Therapeutics Market Size by Application

6 Europe

• 6.1 Europe Mycosis Fungoides Therapeutics Market Size (2014-2019)
• 6.2 Mycosis Fungoides Therapeutics Key Players in Europe
• 6.3 Europe Mycosis Fungoides Therapeutics Market Size by Type
• 6.4 Europe Mycosis Fungoides Therapeutics Market Size by Application

7 China

• 7.1 China Mycosis Fungoides Therapeutics Market Size (2014-2019)
• 7.2 Mycosis Fungoides Therapeutics Key Players in China
• 7.3 China Mycosis Fungoides Therapeutics Market Size by Type
• 7.4 China Mycosis Fungoides Therapeutics Market Size by Application

8 Japan

• 8.1 Japan Mycosis Fungoides Therapeutics Market Size (2014-2019)
• 8.2 Mycosis Fungoides Therapeutics Key Players in Japan
• 8.3 Japan Mycosis Fungoides Therapeutics Market Size by Type
• 8.4 Japan Mycosis Fungoides Therapeutics Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Mycosis Fungoides Therapeutics Market Size (2014-2019)
• 9.2 Mycosis Fungoides Therapeutics Key Players in Southeast Asia
• 9.3 Southeast Asia Mycosis Fungoides Therapeutics Market Size by Type
• 9.4 Southeast Asia Mycosis Fungoides Therapeutics Market Size by Application

10 India

• 10.1 India Mycosis Fungoides Therapeutics Market Size (2014-2019)
• 10.2 Mycosis Fungoides Therapeutics Key Players in India
• 10.3 India Mycosis Fungoides Therapeutics Market Size by Type
• 10.4 India Mycosis Fungoides Therapeutics Market Size by Application

11 Central & South America

• 11.1 Central & South America Mycosis Fungoides Therapeutics Market Size (2014-2019)
• 11.2 Mycosis Fungoides Therapeutics Key Players in Central & South America
• 11.3 Central & South America Mycosis Fungoides Therapeutics Market Size by Type
• 11.4 Central & South America Mycosis Fungoides Therapeutics Market Size by Application

12 International Players Profiles

• 12.1 Azurity Pharmaceuticals Inc.
  • 12.1.1 Azurity Pharmaceuticals Inc. Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Mycosis Fungoides Therapeutics Introduction
  • 12.1.4 Azurity Pharmaceuticals Inc. Revenue in Mycosis Fungoides Therapeutics Business (2014-2019))
  • 12.1.5 Azurity Pharmaceuticals Inc. Recent Development
• 12.2 Celgene Corp.
  • 12.2.1 Celgene Corp. Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Mycosis Fungoides Therapeutics Introduction
  • 12.2.4 Celgene Corp. Revenue in Mycosis Fungoides Therapeutics Business (2014-2019)
  • 12.2.5 Celgene Corp. Recent Development
• 12.3 Eisai Co. Ltd.
  • 12.3.1 Eisai Co. Ltd. Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Mycosis Fungoides Therapeutics Introduction
  • 12.3.4 Eisai Co. Ltd. Revenue in Mycosis Fungoides Therapeutics Business (2014-2019)
  • 12.3.5 Eisai Co. Ltd. Recent Development
• 12.4 Helsinn Healthcare SA
  • 12.4.1 Helsinn Healthcare SA Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Mycosis Fungoides Therapeutics Introduction
  • 12.4.4 Helsinn Healthcare SA Revenue in Mycosis Fungoides Therapeutics Business (2014-2019)
  • 12.4.5 Helsinn Healthcare SA Recent Development
• 12.5 Horizon Therapeutics Plc
  • 12.5.1 Horizon Therapeutics Plc Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Mycosis Fungoides Therapeutics Introduction
  • 12.5.4 Horizon Therapeutics Plc Revenue in Mycosis Fungoides Therapeutics Business (2014-2019)
  • 12.5.5 Horizon Therapeutics Plc Recent Development
• 12.6 Kyowa Kirin Co. Ltd.
  • 12.6.1 Kyowa Kirin Co. Ltd. Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Mycosis Fungoides Therapeutics Introduction
  • 12.6.4 Kyowa Kirin Co. Ltd. Revenue in Mycosis Fungoides Therapeutics Business (2014-2019)
  • 12.6.5 Kyowa Kirin Co. Ltd. Recent Development
• 12.7 Merck & Co. Inc.
  • 12.7.1 Merck & Co. Inc. Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Mycosis Fungoides Therapeutics Introduction
  • 12.7.4 Merck & Co. Inc. Revenue in Mycosis Fungoides Therapeutics Business (2014-2019)
  • 12.7.5 Merck & Co. Inc. Recent Development
• 12.8 Seattle Genetics Inc.
  • 12.8.1 Seattle Genetics Inc. Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Mycosis Fungoides Therapeutics Introduction
  • 12.8.4 Seattle Genetics Inc. Revenue in Mycosis Fungoides Therapeutics Business (2014-2019)
  • 12.8.5 Seattle Genetics Inc. Recent Development
• 12.9 Soligenix Inc.
  • 12.9.1 Soligenix Inc. Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Mycosis Fungoides Therapeutics Introduction
  • 12.9.4 Soligenix Inc. Revenue in Mycosis Fungoides Therapeutics Business (2014-2019)
  • 12.9.5 Soligenix Inc. Recent Development
• 12.10 Takeda Pharmaceutical Co. Ltd.
  • 12.10.1 Takeda Pharmaceutical Co. Ltd. Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Mycosis Fungoides Therapeutics Introduction
  • 12.10.4 Takeda Pharmaceutical Co. Ltd. Revenue in Mycosis Fungoides Therapeutics Business (2014-2019)
  • 12.10.5 Takeda Pharmaceutical Co. Ltd. Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Product (2019-2025)
• 13.2 Market Size Forecast by Application (2019-2025)
• 13.3 Market Size Forecast by Regions
• 13.4 North America
• 13.5 Europe
• 13.6 China
• 13.7 Japan
• 13.8 Southeast Asia
• 13.9 India
• 13.10 Central & South America

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer

This report focuses on the global Mycosis Fungoides Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Mycosis Fungoides Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Azurity Pharmaceuticals Inc.
Celgene Corp.
Eisai Co. Ltd.
Helsinn Healthcare SA
Horizon Therapeutics Plc
Kyowa Kirin Co. Ltd.
Merck & Co. Inc.
Seattle Genetics Inc.
Soligenix Inc.
Takeda Pharmaceutical Co. Ltd.

Market segment by Type, the product can be split into
Small Molecules
Biologics

Market segment by Application, split into
Hospital
Clinic
Other

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Mycosis Fungoides Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Mycosis Fungoides Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Mycosis Fungoides Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.